Treatment with dabrafenib plus trametinib after progression on initial BRAF/MEK inhibition could be effective for patients.
Keith Flaherty, MD, was interviewed about recent findings regarding targeted therapies for melanoma.
Maternal cancer during pregnancy is linked with higher risks of stillbirth and neonatal mortality.
Binimetinib prolonged progression-free survival and was associated with a safety profile for patients with NRAS-mutant melanoma.
In patients with cutaneous squamous cell carcinoma, incidence of RAS, BRAF, and EGFR are low.
Approval of avelumab for the treatment of patients 12 years and older with Merkel cell carcinoma was granted by the FDA.
SK-like melanoma are hard to diagnose, however dermoscopic features can help diagnose them.